Atrium Therapeutics, Inc. Common Stock RNA
$11.35
-20.01%
at last close
Analyst Consensus
- Consensus Rating
- Moderate Buy (7 Buy · 7 Hold · 0 Sell)
- Average Price Target
- $55.31
- Implied Upside
- +387.3%
- Price Target Range
- $25.00 – $74.00
- Analysts (12 mo)
- 14
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-14 | HC Wainwright & Co.Mitchell S. Kapoor |
Reiterates | Buy | $25 |
| 2026-08-06 | HC Wainwright & Co.Mitchell S. Kapoor |
Initiates coverage on | Buy | $25 |
| 2026-06-18 | Cantor FitzgeraldKristen Kluska |
Initiates coverage on | Overweight | $25 |
| 2026-05-15 | Leerink PartnersJoseph Schwartz |
Initiates coverage on | Outperform | $25 |
| 2026-05-01 | HC Wainwright & Co.Ananda Ghosh |
Suspends | Neutral | — |
| 2026-03-11 | Wells FargoYanan Zhu |
Initiates coverage on | Overweight | $25 |
| 2025-11-11 | Chardan CapitalKeay Nakae |
Maintains | Neutral | $72 |
| 2025-10-29 | TD CowenRitu Baral |
Downgrades | Buy → Hold | $78 → $74 |
| 2025-10-28 | Chardan CapitalKeay Nakae |
Downgrades | Buy → Neutral | $75 → $72 |
| 2025-10-28 | RBC CapitalLuca Issi |
Downgrades | Outperform → Sector perform | $61 → $72 |
| 2025-10-27 | CitigroupGeoff Meacham |
Downgrades | Buy → Neutral | $75 → $72 |
| 2025-10-27 | Leerink PartnersJoseph Schwartz |
Downgrades | Outperform → Market perform | $65 → $72 |
| 2025-10-27 | Raymond JamesMartin Auster |
Downgrades | Strong buy → Market perform | — |
| 2025-10-27 | BernsteinWilliam Pickering |
Downgrades | Outperform → Market perform | $52 → $72 |
| 2025-10-27 | NeedhamJoseph Stringer |
Downgrades | Buy → Hold | $65 |
| 2025-10-27 | HC Wainwright & Co.Ananda Ghosh |
Downgrades | Buy → Neutral | $87 → $72 |
| 2025-09-22 | Evercore ISI GroupJosh Schimmer |
Maintains | Outperform | $70 → $65 |
| 2025-09-17 | Roth CapitalBoobalan Pachaiyappan |
Initiates coverage on | Buy | $62 |
| 2025-09-15 | B of A SecuritiesGeoff Meacham |
Maintains | Buy | $56 → $65 |
| 2025-09-12 | HC Wainwright & Co.Ananda Ghosh |
Maintains | Buy | $68 → $87 |
| 2025-09-10 | NeedhamJoseph Stringer |
Maintains | Buy | $60 → $65 |
| 2025-09-10 | Chardan CapitalKeay Nakae |
Maintains | Buy | $75 |
| 2025-08-08 | Wells FargoYanan Zhu |
Maintains | Overweight | $70 → $75 |
| 2025-08-08 | BarclaysGena Wang |
Maintains | Overweight | $59 → $62 |
| 2025-08-08 | Chardan CapitalKeay Nakae |
Maintains | Buy | $75 |
| 2025-07-10 | Goldman SachsCorinne Johnson |
Reinstates | Buy | $55 |
| 2025-06-27 | Cantor FitzgeraldEric Schmidt |
Reiterates | Overweight | $96 |
| 2025-06-17 | Wolfe ResearchAndy Chen |
Initiates coverage on | Outperform | $55 |
| 2025-06-11 | Raymond JamesMichael Freeman |
Initiates coverage on | Strong buy | $65 |
| 2025-06-10 | CitigroupGeoff Meacham |
Maintains | Buy | $70 → $75 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $11.35
- Market Cap
- $194.15 million
- 52-Week Range
- $10.75 – $73.06
- Average Volume
- 198K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.